HaDEA has published a call for tenders HADEA/2023/OP/0036 – “Speed up the development of and access to innovative medical countermeasures”.
The objective of this call is to conclude service contracts for the purchasing of clinical and non-clinical services to speed up availability and access to innovative medical countermeasures (MCMs) to diagnose/detect, prevent, protect from or treat conditions associated to serious cross-border health threats.
DEADLINE EXTENDED: All interested parties are invited to send in their applications by 18 December 2023, 16:00 (CET).
Lots of the call:
Lot 1 will support the assessment of the vaccine candidate’s efficacy and safety (within phase II clinical trials), as well as any development that helps identify the most promising preparation, dose, and schedule to be tested in phase III clinical trials, related to antimicrobial resistance.
Estimated budget: €22 million
Lot 2 will support the assessment of the candidate’s efficacy and safety (within phase II clinical trials) to foster the development of broad-spectrum antivirals targeting respiratory RNA viral families, mainly, but not limited to, Paramyxo-, Orthomyxo- and Coronaviridae, as well as any development that helps identifying the most promising preparation, dose, and schedule, to be tested in phase III clinical trials.
Estimated budget: €18 million
Lot 3 will support the assessment of the candidate’s efficacy and safety (within phase II clinical trials) to foster the development of broad-spectrum antivirals targeting RNA viral families known for causing viral haemorrhagic fever (mainly, but not limited to, Arena-, Bunya-, Flavi- and Filoviridae), as well as any development that helps identifying the most promising preparation, dose, and schedule, to be tested in phase III clinical trials.
Estimated budget: €18 million
Lot 4 will support the development and certification of a metagenomic next-generation sequencing (mNGS)-based device for point-of-care infectious disease diagnostics and early outbreak detection. The device will be able to detect any respiratory viral pathogen, including novel and emerging, delivering a result readable to clinicians within hours while being cost-competitive with current molecular diagnostics.
Estimated budget: €24 million
Estimated total budget: €82 million
Deadline extended: EU4Health call for tenders on innovative medical countermeasures (europa.eu)